Volume 15 (2012)
Volume 11 (2008)
Volume 8 (2005)
Volume 7 (2004)
Volume 6 (2003)
Volume 5 (2002)
Volume 4 (2001)
Volume 3 (2000)
Volume 1 (1998)
Most Downloaded Articles
- Price Shopping in Consumer-Directed Health Plans by Sood, Neeraj/ Wagner, Zachary/ Huckfeldt, Peter and Haviland, Amelia M.
- Health and Health Care of Medicare Beneficiaries in 2030 by Gaudette, Étienne/ Tysinger, Bryan/ Cassil, Alwyn and Goldman, Dana P.
- Fat Taxes: Big Money for Small Change by Chouinard, Hayley H/ Davis, David E/ LaFrance, Jeffrey T and Perloff, Jeffrey M
- A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets by Berndt, Ernst R./ McGuire, Thomas and Newhouse, Joseph P.
The Value of Delaying Alzheimer’s Disease Onset
1Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331, USA
2Davis School of Gerontology, University of Southern California, 3715 McClintock Ave., Los Angeles, CA, USA
3Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA, USA
Citation Information: Forum for Health Economics and Policy. Volume 18, Issue 1, Pages 25–39, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: 10.1515/fhep-2014-0013, November 2014
- Published Online:
Alzheimer’s disease (AD) extracts a heavy societal toll. The value of medical advances that delay onset of AD could be significant. Using data from nationally representative samples from the Health and Retirement Study (1998–2008) and Aging Demographics and Memory Study (2001–2009), we estimate the prevalence and incidence of AD and the formal and informal health care costs associated with it. We use microsimulation to project future prevalence and costs of AD under different treatment scenarios. We find from 2010 to 2050, the number of individuals ages 70+ with AD increases 153%, from 3.6 to 9.1 million, and annual costs increase from $307 billion ($181B formal, $126B informal costs) to $1.5 trillion. 2010 annual per person costs were $71,303 and double by 2050. Medicare and Medicaid are paying 75% of formal costs. Medical advances that delay onset of AD for 5 years result in 41% lower prevalence and 40% lower cost of AD in 2050. For one cohort of older individuals, who would go on to acquire AD, a 5-year delay leads to 2.7 additional life years (about 5 AD-free), slightly higher formal care costs due to longer life but lower informal care costs for a total value of $511,208 per person. We find Medical advances delaying onset of AD generate significant economic and longevity benefits. The findings inform clinicians, policymakers, businesses and the public about the value of prevention, diagnosis, and treatment of AD.